Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Evidence from a Real-World Perspective - Part 2

Author(s): Aliaksei Kisialiou, Giulia Prinzi, Palma Lamonaca, Vittorio Cardaci, Carlo Tomino, Massimo Fini, Stefano Bonassi and Patrizia Russo *

Volume 26, Issue 10, 2019

Page: [1734 - 1745] Pages: 12

DOI: 10.2174/0929867325666181031101128

Price: $65

Abstract

Background: We report a comprehensive overview of current COPD therapies from a real-world experience.

Objective: Critically review the opportunities and the challenges occurring in the real-world treatment of COPD.

Methods: This is a review that also report results from COPD patients treated with standardized therapy including pulmonary rehabilitation (Real World Data – RWD).

Conclusion: Comprehensive assessment of COPD management requires strategies able to evaluate efficacy and usefulness in a real-world population, that take into account the interaction between experience and academic training, research, adherence to guidelines and judgments in order to plan the appropriate and optimum use of available strategies.

Keywords: Classical-therapy, complexity, COPD, personalized-medicine, pulmonary rehabilitation real-world analysis, systems approaches.

« Previous Next »
[1]
Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease Report, 2017. Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ [Accessed: June 9, 2017]
[2]
Barnes, P.J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med., 2014, 35(1), 71-86.
[3]
Postma, D.S.; Bush, A.; van den Berge, M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet, 2015, 385(9971), 899-909.
[4]
Castaldi, P.J.; Cho, M.H.; San José Estépar, R.; McDonald, M.L.; Laird, N.; Beaty, T.H.; Washko, G.; Crapo, J.D.; Silverman, E.K. Genome-wide association identifies regulatory Loci associated with distinct local histogram emphysema patterns. Am. J. Respir. Crit. Care Med., 2014, 190(4), 399-409.
[5]
Schamberger, A.C.; Mise, N.; Meiners, S.; Eickelberg, O. Epigenetic mechanisms in COPD: Implications for pathogenesis and drug discovery. Expert Opin. Drug Discov., 2014, 9(6), 609-628.
[6]
Sherman, R.E.; Anderson, S.A.; Dal Pan, G.J.; Gray, G.W.; Gross, T.; Hunter, N.L.; LaVange, L.; Marinac-Dabic, D.; Marks, P.W.; Robb, M.A.; Shuren, J.; Temple, R.; Woodcock, J.; Yue, L.Q.; Califf, R.M. Real-world evidence - what is it and what can it tell us? N. Engl. J. Med., 2016, 375(23), 2293-2297.
[7]
Price, D.; Hillyer, E.V.; van der Molen, T. Efficacy versus effectiveness trials: Informing guidelines for asthma management. Curr. Opin. Allergy Clin. Immunol., 2013, 13(1), 50-57.
[8]
Woodruff, P.G.; Agusti, A.; Roche, N.; Singh, D.; Martinez, F.J. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: Making progress towards personalised management. Lancet, 2015, 385(9979), 1789-1798.
[9]
van Schayck, C.P.; Folgering, H.; Harbers, H.; Maas, K.L.; van Weel, C. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax, 1991, 46(5), 355-359.
[10]
Donohue, J.F.; Fogarty, C.; Lötvall, J.; Mahler, D.A.; Worth, H.; Yorgancioglu, A.; Iqbal, A.; Swales, J.; Owen, R.; Higgins, M.; Kramer, B. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med., 2010, 182(2), 155-162.
[11]
Barnes, P. Bronchodilators: basic pharmacology. In: Calverley PMA, Pride NB, eds; Chronic obstructive pulmonary disease. London: Chapman and Hall, 1995; pp. 391-417.
[12]
Disse, B.; Speck, G.A.; Rominger, K.L.; Witek, T.J., Jr; Hammer, R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci., 1999, 64(6-7), 457-464.
[13]
Murciano, D.; Auclair, M.H.; Pariente, R.; Aubier, M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N. Engl. J. Med., 1989, 320(23), 1521-1525.
[14]
Taylor, D.R.; Buick, B.; Kinney, C.; Lowry, R.C.; McDevitt, D.G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am. Rev. Respir. Dis., 1985, 131(5), 747-751.
[15]
Fabbri, L.M.; Calverley, P.M.; Izquierdo-Alonso, J.L.; Bundschuh, D.S.; Brose, M.; Martinez, F.J.; Rabe, K.F. M2-127 and M2-128 study groups. Rofumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials. Lancet, 2009, 374, 695-703.
[16]
Rabe, K.F. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol., 2011, 163(1), 53-67.
[17]
Martinez, F.J.; Calverley, P.M.; Goehring, U.M.; Brose, M.; Fabbri, L.M.; Rabe, K.F. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet, 2015, 385(9971), 857-866.
[18]
McDonald, C.F.; Khor, Y. Advances in chronic obstructive pulmonary disease. Intern. Med. J., 2013, 43(8), 854-862.
[19]
Müllerova, H.; Maselli, D.J.; Locantore, N.; Vestbo, J.; Hurst, J.R.; Wedzicha, J.A.; Bakke, P.; Agusti, A.; Anzueto, A. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest, 2015, 147(4), 999-1007.
[20]
Walters, J.A.; Tan, D.J.; White, C.J.; Gibson, P.G.; Wood-Baker, R.; Walters, E.H. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 2014, 9(9)CD001288
[21]
Karner, C.; Cates, C.J. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 2011, 3(3)CD008532
[22]
Horita, N.; Goto, A.; Shibata, Y.; Ota, E.; Nakashima, K.; Nagai, K.; Kaneko, T. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst. Rev., 2017, 2CD012066
[23]
Postma, D.S.; Calverley, P. Inhaled corticosteroids in COPD: A case in favour. Eur. Respir. J., 2009, 34(1), 10-12.
[24]
Suissa, S.; Barnes, P.J. Inhaled corticosteroids in COPD: The case against. Eur. Respir. J., 2009, 34(1), 13-16.
[25]
ClinicalTrials.gov. 2016. Available at: https://clinicaltrials. gov/ct2/show/NCT01218126 [Accessed: February 4, 2016]
[26]
Casanova, C.; Coté, C.; Marin, J.M.; Pinto-Plata, V.; de Torres, J.P.; Aguirre-Jaíme, A.; Vassaux, C.; Celli, B.R. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest, 2008, 134(4), 746-752.
[27]
Enfield, K.; Gammon, S.; Floyd, J.; Falt, C.; Patrie, J.; Platts-Mills, T.A.; Truwit, J.D.; Shim, Y.M. Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. J. Cardiopulm. Rehabil. Prev., 2010, 30(3), 195-202.
[28]
Spruit, M.A.; Polkey, M.I.; Celli, B.; Edwards, L.D.; Watkins, M.L.; Pinto-Plata, V.; Vestbo, J.; Calverley, P.M.; Tal-Singer, R.; Agusti, A.; Coxson, H.O.; Lomas, D.A.; MacNee, W.; Rennard, S.; Silverman, E.K.; Crim, C.C.; Yates, J.; Wouters, E.F. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J. Am. Med. Dir. Assoc., 2012, 13(3), 291-297.
[29]
Takahashi, S.; Betsuyaku, T. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir. Investig., 2015, 53(6), 259-270.
[30]
McGarvey, L.P.; John, M.; Anderson, J.A.; Zvarich, M.; Wise, R.A. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax, 2007, 62(5), 411-415.
[31]
Incalzi, R.A.; Scarlata, S.; Pennazza, G.; Santonico, M.; Pedone, C. Chronic obstructive pulmonary disease in the elderly. Eur. J. Intern. Med., 2014, 25(4), 320-328.
[32]
Vanfleteren, L.E.; Spruit, M.A.; Groenen, M.; Gaffron, S.; van Empel, V.P.; Bruijnzeel, P.L.; Rutten, E.P.; Op ’t Roodt, J.; Wouters, E.F.; Franssen, F.M. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2013, 187(7), 728-735.

Rights & Permissions Print Cite
Article Metrics
50
5
© 2024 Bentham Science Publishers | Privacy Policy